Citadel Advisors
PVLA

Citadel Advisors’s Palvella Therapeutics PVLA Stock Holding History

Citadel Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Buy
13,300
+5,500
+71% +$668K ﹤0.01% 6514
2026
Q1 		$972K Buy
+7,800
New +$814K ﹤0.01% 7719
2024
Q2 		– Sell
-3
Closed -$37 – 15639
2024
Q1 		$37 Sell
3
-51
-94% -$710 ﹤0.01% 14444
2023
Q4 		$783 Hold
54
– – ﹤0.01% 13943
2023
Q3 		$1.28K Hold
54
– – ﹤0.01% 13887
2023
Q2 		$712 Sell
54
-12
-18% -$728 ﹤0.01% 14059
2023
Q1 		$5.17K Buy
66
+15
+29% +$1.74K ﹤0.01% 13886
2022
Q4 		$4.26K Buy
+51
New +$4.1K ﹤0.01% 14114
2022
Q2 		– Sell
-191
Closed -$46K – 14313
2022
Q1 		$46K Buy
191
+32
+20% +$8.41K ﹤0.01% 12849
2021
Q4 		$48K Sell
159
-830
-84% -$266K ﹤0.01% 13276
2021
Q3 		$409K Buy
989
+18
+2% +$6.27K ﹤0.01% 10359
2021
Q2 		$298K Buy
+971
New +$213K ﹤0.01% 11291

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Citadel Advisors's PVLA Position: Q2 2026 in Review

Citadel Advisors reduced its Palvella Therapeutics (PVLA) stake by 83% in Q2 2026, selling an estimated $2.06M and leaving 3,520 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #9682.

Citadel Advisors first reported a position in PVLA in Q4 2017 and has held it in 31 quarters since. The position peaked at $11.9M in Q3 2021. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Citadel Advisors held 3,520 shares of Palvella Therapeutics worth $538K as of Q2 2026.
  • Citadel Advisors sold 16,952 Palvella Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Palvella Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9682 holding.
  • Citadel Advisors first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 31 quarters since.
  • Citadel Advisors's Palvella Therapeutics position peaked at $11.9M in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.